Background: Until recently, few therapeutic options, other than symptomatic treatment, were available for patients with primary progressive multiple sclerosis (PPMS). Ocrelizumab is the only approved treatment in this indication, and only since 2017. However, many patients in France are receiving off-label treatments for PPMS, mainly rituximab, mycophenolate mofetil, methotrexate, cyclophosphamide, and azathioprine.
Objective: To evaluate published data concerning the efficacy of these five treatments frequently used as off-label disease-modifying therapies.
Methods: We reviewed and summarized the studies published in Pubmed since the inception of the database.
Results: Evidence from randomized controlled trials is lacking to support the use of these treatments as disease-modifying therapies in PPMS.
Conclusion: The literature lacks dedicated studies to support the off-label use of these disease-modifying therapies in PPMS. However, some limited data are available in the literature suggesting that the use of rituximab and cyclophosphamide could potentially be of some interest in specific subpopulations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neurol.2022.02.461 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Treating Lupus Nephritis: A Systematic Review.
Cureus
December 2024
Department of Rheumatology, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, USA.
Systemic lupus erythematosus (SLE) is a prevalent autoimmune condition worldwide resulting from the loss of tolerance against self-antigens. The constitutional symptoms of SLE are well-known, including fatigue, fever, myalgia, weight loss, arthralgia, arthritis, malar rash, and photosensitivity. These symptoms often overshadow the impacts SLE can have on all body systems, with the renal system frequently impacted.
View Article and Find Full Text PDFGemcitabine-Based Chemotherapy for Advanced Soft Tissue Sarcoma: Identifying the Appropriate Dose and Schedule.
Cureus
December 2024
Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, JPN.
Background In 2024, reimbursement for gemcitabine-docetaxel therapy (GEM-DOC; gemcitabine 900 mg/m on days 1 and 8 and docetaxel 70 mg/m on day 8 every 21 days, GEM 900-DOC 70) to treat recurrent/metastatic soft tissue sarcoma (STS) was made in Japan. Methods We retrospectively reviewed clinical records of advanced/metastatic STS patients who underwent off-label gemcitabine-containing chemotherapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research between February 2007 and October 2019. Results Of 115 enrolled patients, 51 were treated with GEM-DOC (26 patients received the dose as previously stated) and the other 64 with gemcitabine monotherapy.
View Article and Find Full Text PDFPipeline embolization device for aneurysm recurrence after stent-assisted coiling.
Neuroradiology
January 2025
Department of Neurosurgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Litang Road 168, Beijing, 102218, China.
Objective: Since the emergence of the Pipeline Embolization Device (PED), its off-label use has significantly improved the treatment effectiveness of complex intracranial aneurysms, including the treatment of recurrent aneurysms. Although PED is effective in this situation, there is still a lack of evidence-based medicine for its role in recurrent aneurysms after stent-assisted coiling. The aim of this study is to evaluate the safety and efficacy of PED treatment for recurrent aneurysms after stent-assisted coiling.
View Article and Find Full Text PDFAutoimmune hepatitis, what should be considered when conventional therapies fail?
Rev Esp Enferm Dig
January 2025
Aparato Digestivo, Complejo Asistencial Universitario de León, España.
Autoimmune hepatitis (AIH) is an immune-mediated disease characterised by elevated transaminases, immunoglobulin G and autoantibody positivity. Treatment is based on corticosteroids and azathioprine. Up to 15% of patients will require a second line of treatment, with remission rates after this second line of about 60-75%.
View Article and Find Full Text PDFClinical patterns of vitiligo in Japan: A descriptive study using the JMDC claims database.
J Dermatol
January 2025
Department of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Vitiligo is a chronic autoimmune disorder that profoundly impacts patients' quality of life. Real-world data on vitiligo in Japan are limited. This descriptive, cross-sectional study used a claims database to evaluate vitiligo prevalence, patient demographics, treatments, and comorbidities in Japanese patients with vitiligo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!